MedTrace Logo

Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies

NCT04566614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2025-04-06

No results posted yet for this study

Summary

The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.

Conditions

  • Neoplasm, Colorectal
  • Neoplasm of Lung
  • Neoplasm, Bladder
  • Neoplasms Pancreatic
  • Biliary Tract Neoplasms
  • Gastro Intestinal Stromal Tumour

Interventions

OTHER

ctDNA blood sampling

Screening/baseline blood sample to be analysed for ctDNA

Sponsors & Collaborators

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Justin Mencel, MBBS · Royal Marsden Hospital NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-18
Primary Completion
2023-07-31
Completion
2025-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04566614 on ClinicalTrials.gov